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Abstract
The main challenge in tendon injury management is suboptimal tissue healing that fails to re-establish 
original tendon function. Tissue bioengineering is a promising approach for tendon therapy, with potential 
to improve its functional outcomes. However, evaluation criteria for tissue-engineered tendon are unclear 
due to the lack of specific markers of differentiated tendon. The study aim was to identify a panel of genes 
that characterised tendons in comparison to cartilage or muscles and validate those genes, both in human 
and key species used as models for tendon diseases. Gene expression profiling of rat tendon and cartilage 
in whole-tissue samples and primary tenocytes and chondrocytes was undertaken using two independent 
microarray platforms. Genes that demonstrated high expression correlation across two assays were validated 
by qRT-PCR in rat tendon relative to cartilage and muscle. Five genes demonstrating the highest tendon-
related expression in the validation experiment (ASPN, ECM1, IGFBP6, TNMD, THBS4) were further evalu-
ated by qRT-PCR in ovine, equine and human tissue. The group of tendon markers, identified by unbiased 
transcriptomic analysis of rat musculoskeletal tissues, demonstrated species-dependent profiles of expression. 
Insulin-like growth factor binding protein 6 (IGFBP6) was identified as the only universal tendon marker. 
Further investigation in equine tendon showed that IGFBP6 expression was not affected by ageing or tendon 
function but decreased in anatomical regions subjected to elevated compressive force. IGFBP6 is a robust 
cross-species marker of tendon phenotype and may find application in evaluation of tendon physiology and 
guided differentiation of permissive cells towards functional tenocytes.
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Introduction
The tendon is a highly specialised connective tissue 
that transmits the mechanical force of muscle 
contraction to the bone. Tendon histological structure, 
dominated by dense extracellular matrix (ECM) with 
sparsely distributed resident cells, reflects adaptation 
to high physical demands of tensile strength 
resistance (Thorpe and Screen, 2016). Despite their 
small contribution to the overall tissue mass, tendon 
cells (tenocytes) are primarily responsible for its 
mechano-physical properties, through synthesising 
the bulk of ECM mass during development and 
modifying its composition according to the prevailing 
biomechanical stimuli (Kjær et al., 2009; Testa et al., 
2017; Zhang et al., 2010). Aberrant cell response to 
injury is thought to be one of the causes underlying 
the development of chronic tendinopathies and is 
characterised by changes in ECM organisation which 
are inconsistent with optimal tendon function (Titan 
and Andarawis-Puri, 2016). Alterations in resident cell 
phenotype, primarily chondrogenic differentiation, 
are widely identified in tendinopathies in association 
with degenerate tendon ECM (Asai et al., 2014; 
Burssens et al., 2013; Clegg et al., 2007; Titan and 
Andarawis-Puri, 2016). Therefore, promoting 
functional tendon tissue repair at the injury site and 
directing appropriate cell response subsequent to 
injury are key goals for tendinopathy treatment.
 Tendon bioengineering involves the application of 
tenocytes as well as mesenchymal stem cells (MSCs) to 
develop engineered tendon that may be subsequently 
used as grafts for tendon injury repair (Müller et 
al., 2013). This promising therapeutic approach is 
challenged by the tendency of tendon cells to undergo 
phenotypic transitions when maintained under 
cell-culture conditions (Mueller et al., 2016; Taylor 
et al., 2009; Yao et al., 2006). Tenocyte- and stem-cell-
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derived constructs developed in vitro are at risk of 
cell dedifferentiation and aberrant differentiation 
towards chondrogenic and osteogenic lineages, 
possibly due to the common mesenchymal origin of 
musculoskeletal tissues (Harris et al., 2004; Tan et al., 
2012). In order to evaluate outcomes of tendon tissue-
engineering and further optimise culture conditions 
promoting teno-lineage differentiation, molecular 
markers of a functional adult tendon need to be 
defined. Genes currently investigated in tenocyte 
phenotype characterisation, such as scleraxis (SCX), 
tenomodulin (TNMD), tenascin C (TNC) and type 
1 collagen α1 chain (COL1A1), are often primarily 
derived from developmental studies and their 
validity as markers of mature tenocytes can vary 
depending on tendon type, anatomical region, species 
and age (Howell et al., 2017; Jelinsky et al., 2010; 
Kuemmerle et al., 2016; Mehr et al., 2000; Murchison 
et al., 2007; Peffers et al., 2015; Taylor et al., 2009). 
Moreover, their expression can also be maintained 
in tendons undergoing pathological transformation 
such as fibrosis, cartilage formation or endochondral 
ossification (Agarwal et al., 2017; Howell et al., 2017; 
Mehr et al., 2000) further questioning their utility as 
markers of normal tendon phenotype. Several studies 
utilising unbiased approaches to identify novel 
tendon-selective markers by comparative expression 
profiling of various musculoskeletal tissues have 
been reported (Jelinsky et al., 2010; Kuemmerle et 
al., 2016). However, resilience of these new targets to 
the above described variables has yet to be defined, 
limiting their application to the species, tendon type 
and region they were derived from.
 Rat, sheep and horse are frequently used animal 
models for tendon research (Lui et al., 2011). Rat 
Achilles tendon shows anatomical complexity 
similar to that of humans (Szaro et al., 2012) and 
are suitable for manipulation methods which are 
impractical in larger species (Andarawis-Puri and 
Flatow, 2011; Brunton et al., 2018). The size of sheep 
and equine flexor tendons makes them more suitable 
for investigating the efficacy of clinical interventions 
in experimentally induced tendon lesions (Dahlgren 
et al., 2002; Hausmann et al., 2009; Song et al., 2010). 
Additionally, horse and sheep tendons exhibit a 
hierarchical microstructure analogous to humans, 
with two distinct anatomical compartments: collagen-
rich fascicles and looser interfascicular matrix 
(IFM). The fascicle-IFM interaction is considered to 
play a major role in tendon mechanical behaviour 
(Thorpe et al., 2015); therefore, conservation of that 
microstructure is a highly desirable feature in a 
relevant animal model. The horse is of particular 
interest for tendon research due to the natural 
occurrence of overuse tendinopathy and age-related 
degeneration (Patterson-Kane et al., 2012; Peffers et 
al., 2014), which are also the main disorders affecting 
tendon health in humans (Scott et al., 2015).
 The present study aimed at identifying novel gene 
markers that exhibited clearly higher expression in 
adult tendon relative to cartilage and muscle and 
validated them across the key model species, rat, 
sheep and horse, as well as human tendons.
Materials and Methods
Tissue collection
Tissue collection from different species was 
individually approved by the University of Liverpool 
Institute of Veterinary Sciences Research Ethics 
Committee. Details of sample origin and donor 
demographics are presented in Table 1. Tissues 
from rat were collected under the Schedule I of the 
UK Animal Scientific Procedures Act (1986). Equine 
samples were collected as a by-product of the 
agricultural industry. Sheep tissues were collected 
as part of routine post-mortem examinations for 
Fasciola hepatica at the School of Veterinary Science, 
University of Liverpool. Human cadaveric Achilles 
tendon samples were obtained following ethical 
approval by North East Tyne and Wear South 
Research Ethics Committee (14/NE/0154). Human 
cadaveric femorotibial joint cartilage was obtained 
from a commercial biorepository (ProteoGenex, 
Inglewood, CA, USA) and provided with proof of 
donor consent approval by the local ethical authority 
at the sample collection site. Human muscle samples 
were represented by primary myoblasts isolated from 
muscle biopsy material collected intraoperatively 
from patients undergoing surgical treatment for 
hallux valgus, with patient consent and approval 
from the University of Liverpool, University Hospital 
Aintree Hospital and South West Wales Research 
Ethics Committee (13/WA/0374). Rat, sheep and 
equine whole tissue specimens were dissected and 
stored immediately upon collection in RNAlater™ 
Stabilisation Solution (Invitrogen) according to 
the manufacturer’s protocol (24 h at 4 °C followed 
by long-term storage at − 80 °C). According to 
the information provided by the biobank, human 
cadaveric tendon and cartilage samples were 
preserved by flash-freezing within 30 to 60 min of 
excision in liquid nitrogen and stored at − 80 °C prior 
to RNA isolation.
Histology
To evaluate phenotype of different regions of equine 
SDFT, samples of SDFT midportion and sesamoid 
region were fixed in 10 % buffered formalin for 48-
72 h, dehydrated and embedded in paraffin-wax on 
their longitudinal axis. Then, the tissue blocks were 
cut into 5-μm-thick sections, collected on polylysine 
slides and stained with haematoxylin and eosin 
(H&E).
Cell isolation
Human
Human primary myoblast isolation was undertaken 
according to a previously published method 
(Soriano-Arroquia et al., 2017). Briefly, samples were 
washed in Dulbecco’s phosphate-buffered saline 
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and dissected in a sterile Petri dish in warm (37 °C) 
collagenase-dispase-CaCl2 solution [1.5 U/mL of 
collagenase D, 2.4 U/mL of Dispase II and 2.5 mM 
CaCl2 in serum-free Dulbecco’s modified eagle 
medium (DMEM)] followed by a 40 min incubation in 
50 mL Falcon tube. Digestion was stopped by adding 
sterile growth medium (4 mL of DMEM containing 
20 % foetal bovine serum, 1 % L-glutamine and 1 % 
penicillin-streptomycin) and the sample was filtered 
through a 70 μm cell strainer. Cells were pelleted by 
centrifugation at 443 ×g for 5 min at room temperature 
and stored in TriReagent (Sigma-Aldrich) at − 80 °C 
for RNA isolation.
Rat
In addition to whole tissue samples, expression 
profiling of rat primary tenocytes and chondrocytes 
was undertaken. Primary tenocytes were isolated 
from Achilles tendon (AT) and deep digital flexor 
tendon (DDFT), chondrocytes from femorotibial 
and coxo-femoral joint articular cartilage; both were 
pooled for each individual. Tissue samples were 
minced and washed twice in serum-free DMEM, 
containing penicillin (100 U/mL), streptomycin 
(100 μg/mL) and amphotericin B (2 μg/mL). Cells 
were isolated by collagenase digestion (0.4 %, 
type 2, Worthington) for over 20 h at 37 °C. Next, 
samples were centrifuged: cartilage for 8 min at 
500 ×g and tendon for 15 min at 1,000 ×g, to ensure 
that partially digested fascicular material would be 
spinned-down (Ritty et al., 2003). Supernatant was 
removed and samples incubated for 4 h at 37 °C in 
0.25 % bovine pancreas trypsin (Sigma-Aldrich) in 
serum-free DMEM. Samples were centrifuged as 
Table 1. Detailed description of samples used for respective experiments. Information on donor sex in 
equine samples was not available.
Microarray
Rat, F344 12 weeks; male n = 5
Tendon (AT, DDFT, tail tendon) 
Cartilage (coxo-femoral and 
femorotibial joint) 
Rat, Lewis 12 weeks; male n = 4
Primary tenocytes (AT, DDFT )
Primary chondrocytes (coxo-femoral 
and femorotibial joint)
RT-qPCR cross-species validation
Rat, Lewis 12 weeks; male n = 6
Tendon (AT, DDFT)
Cartilage (coxo-femoral and 
femorotibial joint)
Muscle (quadriceps femoris)
Sheep Adult female n = 6
Tendon (DDFT)
Cartilage (metatarsophalangeal joint)
Muscle (quadriceps femoris)
Horse
9-14 years (11.9 ± 2.2 years) n = 8 Tendon (SDFT midportion)
4-15 years (8.4 ± 6 years) n = 5 Cartilage (metatarsophalangeal joint)
n = 4 Muscle (trapezius)
Human
56-93 years (82.4 ± 15.4 years);
3 female, 2 male n = 5 Tendon (AT midportion)
32-75 years (56 ± 20.8 years);
male n = 6 Cartilage (femorotibial joint)
31-38 years (32.2 ± 2.7 years);
female n = 6
Primary myoblasts
(extensor digitorum brevis, tibialis anterior, 
abductor halluces)
RT-qPCR IGFBP6 in tendon ageing and function
Horse
0 d n = 4
SDFT midportion
0-1 months n = 3
3-6 months n = 4
12-24 months n = 4
3-5 years n = 5
9-11 years n = 5
18-22 years n = 4
3-5 years n = 5 SDFT midportionCDET
5-7 years n = 5 SDFT midportionSDFT sesamoid region
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before, washed with complete medium, re-suspended 
and filtered through a 70 μm sterile cell strainer. Cells 
were pelleted by centrifugation and cell pellets stored 
in TriReagent.
RNA extraction
Whole tissue samples were pulverised under 
liquid nitrogen. Ground-up tissue and cell pellets 
were incubated for 10 min at room temperature 
in TriReagent. RNA was extracted using an acid 
guanidinium thiocyanate-phenol-chloroform method 
(Chomczynski and Sacchi, 2006). Following RNA 
resuspension in 75 % ethanol, DNAse digestion 
and purification were performed using RNeasy 
Mini Kit (QIAGEN). RNA was quantified using 
an ND1000 spectrophotometer (Thermo Fischer 
Scientific). For the microarray experiment, RNA 
integrity was measured using a Bioanalyser (Agilent), 
with all samples obtaining RNA integrity number 
(RIN) scores > 8. In samples used for quantitative 
real-time reverse transcription polymerase chain 
reaction (qRT-PCR), RNA purity was assessed based 
on the A260/A280 absorbance ratio and samples with 
ratio < 1.8 were not accepted for cDNA preparation. 
RNA quantity used for the reverse transcription 
was normalised across different tissue types within 
each species for cross-tissue comparison of gene 
expression.
Rat microarray
Samples
Gene expression profiling of rat tendon was 
undertaken using two independent microarray 
platforms: i) Illumina RatRef v12 platform 
(ArrayExpress accession code: E-MTAB-4800) as 
previously described (Mueller et al., 2016) and ii) 
Affymetrix GeneST Rat platform. Sample preparation 
for the two platforms differed as follows: i) RNA 
was extracted from whole tendon and cartilage from 
12-week-old male F344 rats (n = 5) for profiling by 
Illumina microarray; ii) RNA extraction for Affymetrix 
profiling was derived from primary tenocytes and 
chondrocytes isolated as described above from 
tissues obtained from 12-week-old male Lewis 
rats (n = 4). Sample preparation for each platform 
followed the standard protocol recommended by 
each manufacturer. Illumina microarray profiling 
was performed by The Genome Centre, Queen Mary, 
University of London, UK. Affymetrix microarray 
profiling was performed by Tepnel Pharma Services, 
Hologic Ltd., Manchester, UK.
Data analysis
Raw gene expression data from both platforms 
was pre-processed and interrogated using software 
packages implemented in R (Web ref. 1). Expression 
data were log2-transformed and normalised (loess) 
across all samples. Differential expression analysis 
was performed using methods previously described 
(Smyth, 2005). Pearson’s correlation coefficient was 
calculated for genes differentially expressed in 
tendon in both platforms.
Quantitative real-time PCR
Samples
Candidate marker genes identified in the rat 
microarray were further validated in different 
musculoskeletal tissues of human and key model 
species by qRT-PCR. A summary of sample 
information is presented in Table 1. Briefly, tissue 
samples included: i) whole tendon, cartilage and 
muscle from rat, sheep and horse; ii) human whole 
tendon, cartilage and isolated primary myoblasts.
 Insulin-like growth factor binding protein 6 
(IGFBP6) expression was further analysed in equine 
superficial digital flexor tendon (SDFT) in relation 
to age and anatomical location. RNA extracted from 
the SDFT midportion was analysed across different 
age groups, from full formed foetuses to old horses 
(Table 1). To investigate the impact of anatomical 
differences on IGFBP6 expression in tendons, the 
SDFT midportion was compared to the SDFT 
sesamoid region (compressed by proximal sesamoid 
bones) in young mature horses. Additionally, 
expression in energy-storing SDFT and positional 
common digital extensor tendon (CDET) was 
compared to determine the relation between tendon 
function and IGFBP6 expression.
Primers
Primers were designed using NCBI PrimerBlast 
(Ye et al., 2012) against the most recent published 
record (04/2016). All primers were species-specific 
and amplification efficiency was calculated using 
tendon cDNA in six 10-fold serial dilutions. Primer 
efficiencies were used to correct normalised cycle 
threshold (Ct) values (Pfaffl, 2006). All primers were 
sourced from Eurogentec S.A. (Liege, Belgium) except 
for equine TNMD, which was custom designed by 
PrimerDesign (UK), and human IGFBP6 and TNMD, 
which were provided by Bio-Rad. The sequences of 
custom-designed primers are provided in Table 2.
cDNA production and qRT-PCR
Reverse transcription was performed using M-MLV 
reverse transcriptase and random-hexamer 
oligonucleotides (all Promega). Quantitative PCR 
(qPCR) was performed on a LightCycler 480 II 
(Roche) using 96-well plates (STARLAB). Negative 
controls (cDNA) were included for each primer test. 
A proprietary qPCR SYBR™ master mix (Takyon™, 
no ROX passive reference dye, deoxythymidine 
triphosphate (dTTP); Eurogentec S.A.) was used for 
all analyses apart from human IGFBP6 and TNMD 
where Sso Advanced™ master mix by Bio-Rad was 
used. The manufacturer’s recommended protocol 
for PCR was used: briefly, enzyme activation 
(3 min, 95 °C) followed by 40 cycles consisting of 
denaturation (3 s, 95 °C) and annealing-extension 
(20 s, 60 °C). Products of qPCR amplification were 
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identified as the most stable gene in all tissue types 
and used for relative expression quantification. 
Normalised Ct data were converted to the linear 
form (E−ΔCt) for statistical analysis.
Data analysis
Following Shapiro-Wilks test for normality and 
Levene’s tests for equality of variances, differences 
between conditions were analysed by one-way 
ANOVA with Tukey post-hoc test (equal variance 
between groups), Welch ANOVA with Games-
Howell post-hoc test (unequal variance between 
groups) or Kruskal-Wallis test with Dunns pairwise 
comparison (non-parametric data).
assessed for specificity by melting curve analysis. 
Gene expression levels were normalised to reference 
genes, using the efficiency corrected comparative 
Ct method (Pfaffl, 2006), with all qPCR reactions 
performed in triplicate. Reference genes ribosomal 
protein S20 (Rps20) and ribosomal protein L13a 
(Rpl13a) were shown to have the most stable 
expression across sample types in rat using the 
geNorm algorithm (Vandesompele et al., 2002) 
and geometric mean of their expression used for 
relative expression quantification in that species. 
Therefore, RPS20 was used as reference gene in 
sheep and horse. In human samples, glyceraldehyde 
3-phosphate dehydrogenase (GAPDH)  was 
Fig. 1. Correlation plot of log2 fold changes of independent gene expression profiling studies of rat 
tendons. Genes found to be differentially expressed between native cartilage (top right quadrant) and 
tendons (bottom left quadrant) in both Illumina (x-axis) and Affymetrix (y-axis) datasets plotted by log2 
fold-change. For clarity only, some data points are annotated. Data points are defined as correlated or 
anti-correlated in the relationship key. Where genes have the same directional change, the data point is 
defined as a dark dot, whereas genes with conflicting (anti-correlated) expression changes are defined as 
grey points (see relationship legend). For tendons, Tnmd, Igfbp6, Serpin1, Mfap5 and Ecm1 are all highly 
expressed in two independent datasets. 
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Results
Microarray analysis of rat tendon expression 
markers
Between rat cartilage and tendon gene expression 
profiles, 311 genes were commonly differentially 
expressed across two studies. Of these, 71 did not 
match in the direction of the fold change (decrease or 
increase in expression) between microarray platforms 
(Fig. 1). A moderately high correlation was observed 
between the fold changes of the 311 common genes 
(cor = 0.66, p < 2.2e-16). Genes that demonstrated the 
highest expression in tendon relative to cartilage 
in both studies included: Tmnd, Serpinf1, Igfbp6, 
Cpxm2, Cryab, Ecm1, Mfap5, Myoc, Aspn, Thbs4 (log2 
fold change > 1.5) (Table 2). Other tendon-related 
genes demonstrated more variable expression. A 
list of the top tendon-related genes in rat with their 
respective log2 fold-change values is presented in 
Table 3. When genes showing higher expression 
in tendon were functionally annotated using gene 
ontology terms, the following biological process 
and cell compartment terms were significant after 
adjustment for multiple testing (p < 0.05): blood vessel 
development, developmental process, extracellular 
matrix. Interestingly, annotations specifically 
referencing tendon were not identified.
qPCR validation of putative markers
Validation of relevant tendon markers from a 
group of genes defined in the correlation study was 
undertaken relative to both cartilage and skeletal 
muscle in rats. This represented a third independent 
cohort. Genes selected for validation were inferred 
from correlation plot (Fig. 1) and highlighted in Table 
3. Expression of developmental tendon markers 
Scx and Mustn1 was additionally investigated 
alongside target genes derived from the microarray 
experiment. Significantly higher (p < 0.05) expression 
in tendon as compared to cartilage and muscle was 
detected for Aspn, Cpxm2, Ecm1, Igfbp6, Mfap5, Myoc, 
Serpinf1, Tnmd and Thbs4. Expression of the tendon 
development gene SCX was increased relative to 
cartilage, but not to muscle. Mustn1 and Cryab 
expression was similar in tendon as compared to 
other musculoskeletal tissues.
Table 2. Primer sequences for custom-designed oligonucleotides.
Gene Forward Reverse
Rat
Aspn CCGAAAGGACTACCACCAACT TTGTTTCCAAGACCCAGCCT
Cpxm2 GGCCTATGAAGGAGGTTCCG CTCCCAGAGCAGCGTGTTTA
Cryab AAGAGCGCCAGGACGAAC ACTCCATCCGATGACAGGGA
Ecm1 CCGTGACCAGTTCTTACCCC CTGAAACCTTGAAGGCTCCCT
Igfbp6 CCGTCGGAAGAGACTACCAAG CTTGAACAGGACTGGGCCTT
Mfap5 GCCAACGAGGAGATGACGTA GTCATCCGTGGAAGGTGTGA
Mustn1 TTGCCTGTGGCTACTGCCTGC GAGTGCCAGCCTCGGACATGG
Myoc GAGGGAGACAAAGGATGTGGAG CAGTGATTGTCTCAGCTGTCCT
Scx CCAGAGACGGCGGCGAGAAC TTGGCTGCTGTGGACCCTCCT
Serpinf1 TGCCTTACTTCAAGGGGCAG GTCCTGTCCTCGTCCAGGTG
Thbs4 AGTACCGCTGTAACGACACC GGTTTGGGCGTTTGAGAAGG
Tnmd CCGCCGCACCAGACAAGCAA GGCAGTAGCGGTTGCCTCGAC
Rps20 CCGCTGTTCGCTCCTGCTGA TGCGGCTGGTGAGCGTGATT
Sheep
ASPN GATCTGCAAAGGCTGGGTCT TCACACGTGGTATGTTAGCAAGA
ECM1 GCTGTGCTGAGGAGGAGAAAT GCAGAGTCTCGCCAGAAGTT
IGFBP6 AGGAACTCGGGGACCTCTAC CAGCACGGAGTCCAGATGTT
THBS4 GACACCAGAGACGGCTTTCA GGGGTGGTACTTGCACTCAT
TNMD ATCCCACTCTAATAGCAGTTTCAGA CACCCACTGCTCGTTTTGTT
RPS20 GAAGGTGTGTGCTGACCTGA CTCAGAGTCTTGGTAGGCATCC
Horse
ASPN ACGCTTTACACGTTCTGGAGAT CTCCTTCAAATGCCCCTGGT
ECM1 CCAGGGTGAGACCCTCAATTT GCATCCTCCCACACGAGTT
IGFBP6 GAACCGCAGAGACCAACAGA ACGGGCCCATCTCCGT
THBS4 AATCCTGACAGACCCCACCC GGTAGCGGAGGATGGCTTTGTT
RPS20 TTTGGAGAAGGTGTGTGCTGA GTCTTGGTGGGCATCCGAA
Human
THBS4 GTTGCAGAACCTGGCATTCAG CCCTGGACCTGTCTTAGACTTCA
GAPDH ATGGGGAAGGTGAAGGTCG TAAAAGCAGCCCTGGTGATGACC
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Table 3. Top 40 differentially expressed genes in rat tendon as compared to cartilage resulting from two 
independent microarray studies. Only the genes with matching direction of log2 fold change between 
platforms were included. Genes highlighted in bold were selected for validation with RT-qPCR in rat 
tendon, cartilage and muscle.
Tendon marker analysis in human and model 
species
Genes showing the highest expression in tendon 
(ASPN, ECM1, IGFBP6, TNMC and THBS4), with 
p < 0.001, were selected for further evaluation in 
sheep and horse (Fig. 2a). Unlike in rat, ECM1 
expression was higher in cartilage for both sheep 
and horse; ASPN had high expression in horse 
tendon, but not in sheep. Therefore, only IGFBP6, 
TNMD and THBS4 were additionally analysed in 
human musculoskeletal tissues (Fig. 2a). Expression 
of THBS4 was highly variable but showed a trend 
towards higher expression in all species’ tendons. 
Higher expression of TNMD was confirmed in rat, 
sheep and human but not equine tendon. Only 
IGFBP6 demonstrated significantly higher expression 
in tendon relative to cartilage and muscle in all 
species (Fig. 2a). Therefore, nucleotide sequence 
Gene 
symbol Gene name
Log2 fold change
Ilumina Affymetrix
Serpinf1 Serpin family F member 1 4.4682858 1.8204873
Tnmd Tenomodulin 4.1729279 6.4517042
Igfbp6 Insulin-like growth factor binding protein 6 3.4772336 5.6566756
Cxcl13 Chemokine (C-X-C motif) ligand 13 3.4282285 2.222346
Ecm1 Extracellular matrix protein 1 3.3686932 4.2056954
Cdh13 Cadherin 13 3.3125358 2.1872266
Mfap5 Microfibril associated protein 5 3.2807773 4.8933617
Cpxm2 Carboxypeptidase X, M14 family member 2 3.103086 4.9246271
Nid1 Nidogen 1 3.0072092 2.128184
Aspn Asporin 2.7472203 2.9400469
Lamc1 Laminin subunit gamma 1 2.4477262 1.164511
Thbs4 Thrombospondin 4 2.36365 2.3545135
Clic5 Chloride intracellular channel protein 5 2.1707479 1.0681173
Lama4 Laminin subunit alpha 4 2.1538213 1.463447
Has1 Hyaluronan synthase 1 2.1369792 1.0421126
Nexn Nexilin 2.1266246 0.5113326
Cd151 Cluster of differentiation 151 1.9624259 1.316076
Cryab Crystallin alpha b 1.8879595 5.0390885
Meox2 Mesenchyme homeobox 2 1.8666559 0.5582083
Ccdc3 Coiled-coil domain containing 3 1.8304224 2.0541286
Prss23 Serine protease 23 1.8265794 2.4828796
S100a4 S100 calcium binding protein A4 1.8254947 2.2765567
Itgbl1 Integrin subunit beta like 1 1.7264565 2.909726
Crip2 Cysteine rich protein 2 1.6683555 2.4204807
Myoc Myocilin 1.6593264 5.0361836
Agtr1a Angiotensin II receptor type 1a 1.6040215 1.3105763
Lmcd1 Lim and cysteine rich domains 1 1.5583528 2.1135088
Nbl1 NBL1, DAN family BMP antagonist 1.4990361 3.6254119
Fbln2 Fibulin-2 1.4933224 2.6278954
Rgs4 Regulator of G protein signaling 4 1.4458768 0.8312598
Cygb Cytoglobin 1.4163564 0.5405094
Sncg Synuclein gamma 1.3867141 1.3627389
Procr Protein C receptor 1.3833375 2.3241227
Thbd Thrombomodulin 1.3626751 2.4577927
Chrnb1 Cholinergic receptor nicotinic beta 1 subunit 1.3621048 1.9674221
Ltbp4 Latent transforming growth factor β binding protein 4 1.3502595 3.938885
Lamb2 Laminin subunit beta 2 1.3499291 2.5700232
Cfb Complement factor b 1.2835458 3.008987
Lama2 Laminin subunit alpha 2 1.2763259 2.717257
Mustn1 Musculoskeletal, embryonic nuclear protein 1 1.2715101 2.9484326
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identity of IGFBP6 across the species was evaluated 
using NCBI BLAST (Altschul et al., 1997) (Fig. 2b).
IGFBP6 in equine tendon with relation to function 
and age
Expression of IGFBP6 in a region of equine SDFT 
subjected to compressive force and, thus, displaying 
more fibrocartilage-like morphology was lower 
than in the SDFT tensional midportion (Fig. 3b). No 
significant difference in expression was observed 
between energy-storing (SDFT) and positional 
tendon (CDET), with SDFT expression results 
showing bigger individual variation than CDET 
(Fig. 3c). IGFBP6 expression increased between 0 d 
and 12-24 months of age, followed by stabilisation 
at lower level in the older age groups (3-5, 8-11 and 
18-22 years); however, none of those age-related 
differences achieved statistical significance (Fig. 3d).
Discussion
Evaluation of bioengineered tendon constructs 
and native tendon tissue is based predominantly 
on histological examination and a limited pool of 
molecular markers often not tested for potential 
species-, age- and function-related differences among 
tendons. In the present study, a group of genes, 
identified by unbiased microarray analysis in rat 
native tendon and primary tenocytes, was validated 
across several species relevant for tendon studies 
and confirmed in human. Among those targets 
were genes previously recognised as tendon-specific 
(TNMD, THBS4) (Docheva et al., 2005; Hauser et al., 
1995; Jelinsky et al., 2010) or known to be expressed 
in tendon but not subjected to direct comparisons 
with other adult musculoskeletal tissues (IGFBP6, 
ASPN, ECM1) (Dahlgren and Nixon, 2005; Henry et 
al., 2001; Jelinsky et al., 2010; Kuntz et al., 2018). It is 
worth noting that potential markers identified were 
limited to genes included in the microarray platforms 
and other tendon-specific genes could be identified 
should a similar approach be employed using RNA 
sequencing.
 Primarily, candidate tendon markers should 
be able to differentiate clearly between tendon 
and cartilage as chondrogenic transformation is a 
common feature of degenerated tendon (Asai et al., 
2014; Burssens et al., 2013; Clegg et al., 2007; Titan and 
Andarawis-Puri, 2016). ECM1 and ASPN, although 
highly expressed in rat tendons, showed similar or 
higher expression level in sheep and horse cartilage, 
thus reducing their usability as tendon markers. 
That ambiguity in gene expression is in concordance 
with previous studies. ECM1 is more expressed 
in porcine Achilles tendon enthesis (tendon-bone 
Fig. 2. RT‐qPCR validation of candidate marker genes identified using microarray analysis across 
musculoskeletal tissues in rat, sheep, horse and human. (a) Data were normalised to Rps20 and Rpl13 (rat), 
RPS20 (horse and sheep) and GAPDH (human) and presented as efficiency corrected 2−ΔCt. Bars represent 
the average expression and standard deviation for each group. A significant difference between average 
expression in cartilage (C), muscles (M) and tendons (T) was marked as: a p < 0.001, b p < 0.05 as determined 
using one-way (equal variances) or Welch (unequal variances) ANOVA. (b) Nucleotide sequence identity of 
IGFBP6 across the species investigated determined as statistically significant by NCBI BLAST (E-value < 1e-92). 
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insertion) than tendon body (Kuntz et al., 2018) and 
ASPN in human adult cartilage, although with no 
reference to expression levels in other tissues (Henry 
et al., 2001). Interestingly, SCX used in the rat RT-
qPCR experiment as a benchmark tendon marker 
(not derived from the current microarray analysis) 
showed substantial variability between individual 
tendon samples, not observed in muscle or cartilage 
and contributing to loss of significance when 
comparing average expression among tissues (Fig. 
2a). Similarly, Mohawk (MKX) gene, known to be 
critical in tendon development, despite being present 
in both microarray platforms, was not significantly 
higher in tendons than in cartilage. SCX is known for 
its key role in tendon development and differentiation 
(Schweitzer et al., 2001); however, its expression in 
tendons declines with their maturation (Chen et 
al., 2017) and can be affected by tendon mechanical 
environment (Murchison et al., 2007; Scott et al., 2011). 
Therefore, it is possible that SCX expression in adult 
tendons is more susceptible to differences in local 
biomechanical factors or individual activity levels. 
SCX regulates expression of another tendon marker 
investigated, TNMD (Shukunami et al., 2006). Results 
confirmed tendon-specific expression of TNMD in 
all species apart from horse, where high variability 
among biological replicates and no clear difference 
in expression among tissues were found (Fig. 2a). 
This finding is supported by previous equine tendon 
marker studies (Kuemmerle et al., 2016; Taylor et al., 
2009) and may challenge the frequent application of 
TNMD as a marker of tendon healing and tenogenic 
differentiation of stem cells in horse (Barsby and 
Guest, 2013; Durgam et al., 2016; Smith et al., 2015). 
Regulation of TNMD transcription is complex and 
involves SCX-independent mechanisms, such as 
Wnt/β-catenin signalling (Katsuhiko et al., 2014), 
which is responsive to mechanical stimulation 
in other musculoskeletal tissues (Lara-Castillo et 
al., 2015; Niu et al., 2016), potentially enhancing 
individual differences in TNMD mRNA levels. The 
reason for variable expression of THBS4 in human 
musculoskeletal tissues in the present study was 
not clear. THBS4 may be abundantly expressed in 
muscle (Frolova et al., 2014); however, it is expected 
to show good separation between tendon and 
cartilage (Jelinsky et al., 2010). Recent work [Simpson 
et al., (2019) Isotopic labelling reveals diverse rate 
of protein turnover within tendon. In: 2019 Annu 
Meet Orthop Res Soc Austin, TX, USA] on use of 
isotopic labelling for evaluation of protein turnover 
rate within tendons has demonstrated that THBS4 is 
the most quickly metabolised ECM protein, which 
perhaps is also reflected by fluctuations at the gene 
Fig. 3. The effect of age and anatomical location on IGFBP6 expression in equine tendons determined by 
RT-qPCR. (a) Schematic view of investigated structures in equine distal limb (tendons marked in black). 
CDET function is to stabilise the limb joints (positional tendon) while SDFT plays a role in locomotion 
(energy-storing tendon). SDFT sesamoid region is subjected to compression by adjacent proximal sesamoid 
bones affecting tendon morphology. Expression of IGFBP6 was compared in (b) two regions of SFDT – 
sesamoid and midportion. Images below the graph present differences in histological structure of the two 
regions (haematoxylin and eosin stain, scale bar = 100 μm); (c) functionally distinct tendons, SDFT and 
CDET; (d) SDFT during postnatal development and ageing. Data were normalised to RPS20 and presented 
as efficiency corrected 2−ΔCt. Bars represent the average expression and standard deviation for each group. 
Significant difference between average expression in each group was marked as: a p < 0.001, b p < 0.05 as 
determined using (a,b) t-test or (c) Kruskal-Wallis test with Dunns pairwise comparisons. 
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expression level. Results discussed above add to the 
general conclusion that species can have a significant 
effect on tendon gene expression and that an optimal 
tendon marker should facilitate translation between 
animal experiments and human clinical studies.
 Among the initial pool of candidate tendon 
markers, IGFBP6 was the only gene consistently 
more expressed in tendons as compared to cartilages 
and muscles across different species. This finding, 
combined with high nucleotide-sequence identity 
(Fig. 2b), may suggest IGFBP6 homology and 
conservation of its evolutionary function across 
species. Expression of IGFBP6 in tendon has 
previously been shown in a human microarray study 
comparing a wider group of tissue types including 
bone, bone marrow, cartilage, fat and muscle 
(Jelinsky et al., 2010). IGFBP6 is the main regulator of 
insulin growth factor II (IGF-II) availability and it also 
displays several IGF-II-independent actions affecting 
cell proliferation, survival, differentiation and 
migration (Bach, 2016). IGFs stimulate proteoglycan, 
collagen and non-collagen synthesis in flexor-
tendon-derived cells (Abrahamsson, 1997) and 
causes cell proliferation in both the epitenon and 
endotenon (Murphy and Nixon, 1997). Thus, proteins 
regulating their activity may have a significant role 
in ECM remodelling relevant for tendon physiology. 
Decreased expression of IGFBP6 was described in an 
equine model of tendon injury and human fibroblasts 
from Dupuytren’s disease tissue (Dahlgren et al., 
2006; Raykha et al., 2013) and altered methylation of 
IGFBP6 promoter was detected in a chemical model 
of murine tendinopathy (Trella et al., 2017). In the 
present study, fibrocartilaginous transformation of 
the equine SDFT region compressed by sesamoid 
bones (similar to patellar compression of quadriceps 
femoris tendon in humans) was associated with lower 
IGFBP6 expression (Fig. 3), indicating that not only 
can it discriminate between different mesenchymal 
tissue lineages but also react to phenotype change 
within fully differentiated tendon tissue. A trend 
for increasing levels of IGFBP6 in SDFT postnatal 
development could reflect gradual restriction of 
growth factor accessibility corresponding with 
reaching musculoskeletal maturity (two years of age 
in the horse), when IGFBP6 level stabilised (Fig. 3d). 
The lack of a significant effect of ageing or function 
(positional versus energy-storing tendon) on IGFBP6 
expression suggests its robustness as a biomarker 
of tendon phenotype, which may be desirable in 
the context of a practical application. In the light of 
the current evidence, IGFBP6 expression appears 
to be useful in recognition of a functional tendon 
phenotype and may potentially become employed 
in evaluating tendon degeneration in intra-operative 
and biopsy tendon samples. However, that would 
require further investigation of IGFBP6 expression 
in fibrous scar tissue resulting from tendon injuries, 
for instance by analysing overload lesions frequently 
diagnosed in human and equine athletes. Fibrous 
tissue produced during tendon healing has altered 
microstructure and ECM composition (e.g. increased 
proportion of type III to type I collagen) which results 
in compromised mechanical properties and high 
risk of re-injury (Yang et al., 2014). A gene marker 
differentiating intact from repair tissue could inform 
decision on the extent of tendon dissection during 
surgical management of shoulder tendon injuries. 
Another important direction in tendon marker 
application is quality assessment of engineered 
tissues for use in tendon lesion repair. Previously 
published datasets comparing transcriptomic profiles 
of rat tenocytes and chondrocytes maintained 
in different culture systems and in native tissue 
(Mueller et al., 2016) showed that IGFBP6 expression 
in tendon-derived cells is consistently higher than in 
those derived from cartilage, independently of the 
culture method [monolayer or three-dimensional 
(3D) tissue construct]. Particularly interesting is that 
IGFBP6 maintained higher expression in late passage 
monolayer tenocytes despite the general loss of a 
tissue-specific transcriptomic signature. Dedicated 
studies investigating IGFBP6 at different stages of 
tendon construct creation and relating the expression 
level to structural and functional outcomes are 
needed to validate its use in directed tendon construct 
differentiation.
 Limitations associated with the study, mainly 
pertained to collection of a sample range from 
different tissue types and species. Unlike rat, sheep 
and horse, human tendon, cartilage and muscle 
samples were collected from different donor groups, 
with muscle donors being considerably younger than 
cartilage and tendon donors. That difference is related 
to the fact that healthy cartilage and tendons for 
research are mainly derived from cadaveric sources, 
while muscles can be collected intraoperatively or as 
biopsy samples. Age disparity could have potentially 
affected comparability of expression results from 
different musculoskeletal tissues. Nevertheless, 
two studies analysing age-related changes in 
human tendon and cartilage transcriptome by RNA 
sequencing did not identify any of the marker genes 
investigated in the present study to be differentially 
expressed between young old subjects (Peffers et 
al., 2013; 2015). Results of IGFBP6 analysis in horse 
further demonstrated that growth and development 
are more likely to affect expression of tendon marker 
genes than ageing. Another potential source of 
variation in gene expression levels was the circadian 
rhythm, as it was not possible to control for sample 
collection time in most species, except for rats. The 
available studies investigating circadian changes in 
mouse tendon indicated that only THBS4 expression 
is rhythmic (Yeung et al., 2014). It is also unclear if 
species considered in the present study have the 
same tendon circadian clock. Additionally, analysis 
of bone alongside tendon, cartilage and muscle 
would be desirable as ectopic ossification is one of 
the manifestations of tendon degeneration (Agarwal 
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et al., 2017). However, it is suspected that appearance 
of osteoblasts, responsible for tissue mineralisation in 
tendon, is preceded by fibrocartilaginous metaplasia 
of tenocytes. According to the present study, that 
change is associated with a marked decrease in 
IGFBP6 expression level. IGFBP6 has been also shown 
to be involved in mechanisms inhibiting human 
osteoblast phenotype development (Yan et al., 2001). 
Whilst IGFBP6 expression appears to be a reliable 
marker of tendon tissue, similar relations may not 
necessarily occur at the protein level. Validation of 
the results described in the present study would be 
required to introduce the use of IGFBP6 in protein-
based assays, opening additional avenues for its 
clinical application. In order to establish IGFBP6 as 
clinical marker of healthy tendon phenotype, present 
results would need to be validated by an independent 
cohort study comparing the effect of age, sex and 
pathologies on IGFBP6 expression.
Conclusion
IGFBP6 was identified as a universal transcriptomic 
marker in rat, sheep, equine and human tendons and 
may constitute a potential reference biomarker for 
evaluation of tendon physiological phenotype and 
directed development of engineered tendons.
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Discussion with Reviewers
Linda Dahlgren: Do you think that IGFBP6 would 
be differentially expressed between tendon and a 
general fibrous connective tissue? Or between tendon 
fibroblasts passaged in culture and primary tendon 
fibroblasts?
Authors: Gene expression profiles of rat primary 
tenocytes, tenocytes cultured in monolayer (passage 
3) and 3D fibrin constructs (unpublished data, 
presented at British Society for Matrix Biology 
Spring Meeting, 2019) were compared. IGFBP6 was 
significantly more expressed [log2 fold change > ± 0.5, 
false disovery rate (FDR) < 0.01, log-odds ratio of 
expression > 0] in primary cells and monolayer 
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culture than in 3D constructs. Also, higher expression 
of IGFBP6 was observed in equine tendon cultured 
in monolayer (passage 3) than in 3D fibrin construct, 
as measured by RT-qPCR. Tenocytes cultured in 
monolayer lose their specific phenotype (Muller et al., 
2016; Yao et al., 2006). Therefore, higher expression of 
IGFBP6 in primary than in cultured tenocytes could 
further support its importance as a tendon marker. 
However, it is unclear why monolayer cells would 
show higher IGFBP6 transcript level than tenocytes 
cultured in a 3D system showing more similarity 
to the native tissue in global expression profile 
(Yao et al., 2006). This observation might question 
IGFBP6 usability for tendon engineering purposes 
or the value of the applied 3D culture technique 
for tendon phenotype maintenance. It is likely that 
IGFBP6 declines with culture time as generating 3D 
bioengineered tendon requires significantly more 
time than reaching confluence in cell monolayer. 
Evaluating IGFBP6 expression in a range of tendon 
in vitro models, including novel multifactorial culture 
systems, is needed to validate its application as 
tendon marker for bioengineering application.
Brianne Connizzo: Is IGFBP6 expressed highly in 
other non-musculoskeletal tissues that might be 
present in vivo, such as vascular or adipose tissues?
Authors: IGFBP6 is expressed across multiple tissues. 
The Human Protein Atlas (additional Web ref. 1) 
utilising mRNA expression data derived from RNA 
deep-sequencing studies of healthy tissues reports 
high expression levels of IGFBP6 in adipose tissue, 
endocrine and gastrointestinal systems, further 
confirmed by the report of The Genotype-Tissue 
Expression (GTEx) portal (additional Web ref. 2). All 
tendon samples analysed in the present study were 
dissected from the tendon midportion, limiting the 
possibility of including adipose or loose vascular 
connective tissue located in the paratenon. IGFBP6 
cannot be considered as a tendon-specific gene, 
however, the expression difference between tendon 
and other musculoskeletal tissues and between 
different tendon phenotypes might be relevant in the 
context of tendon tissue engineering and detecting 
fibrocartilaginous degeneration.
Brianne Connizzo: How much of the conclusions do 
you think could be driven by variability in the data? 
Or what does the higher variability in tendon as 
compared to other tissues indicate about expression 
of these genes?
Authors: Target genes were chosen based on 
expression across two microarray platforms that were 
highly correlated for tendon (that was the selection 
criteria). Relative expression of many of these genes 
in cartilage and muscle is very low and should not 
be confused with ‘very consistent’. Expression of 
certain genes in tendon may vary with site, age, 
injury and what seen may reflect the variation in the 
population. However, answering such a question 
was beyond the scope of the study due to the limited 
sample size and demographic characterisation of the 
investigated tissues.
Brianne Connizzo: How does expression of IGFBP6 
change in injured or diseased tendon? Can this be 
used to identify varying levels of injury?
Authors : Previous studies report decreased 
expression of IGFBP6 in animal models of tendon 
injury and human fibrotic disease of the palmar 
fascia (Dupuytren’s disease) (see Discussion). Time-
series study utilising collagenase-induced lesions 
of equine SDFT showed that IGFBP6 expression 
declines in response to the insult, however, it 
returns to pre-injury level within three months of 
injury (Dahlgren et al., 2006). That may suggest that 
tracking IGFBP6 expression change could indicate 
healing progress in acute tendon injuries if those 
finding would have been validated in naturally 
occurring disease. Preliminary experiment (data not 
published) demonstrated a significant decrease in 
IGFBP6 expression in early but not advanced rotator 
cuff tendinopathy as compared to healthy hamstring 
tendon. Those promising results warrant further 
investigation of IGFBP6 expression in tendon health 
and disease. However, discussing IGFBP6 role in 
tendon pathology was beyond the scope of the study 
as results described gene expression only in healthy 
tissue samples.
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Editor’s note: The Scientific Editor responsible for 
this paper was Juerg Gasser.
